Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

NCT04055493 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1684

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Female

Interventions

DRUG: Ribociclib 200Mg Oral Tablet

Sponsor

West German Study Group

Collaborators

[object Object]
[object Object]